普罗布考联合阿托伐他汀治疗急性冠脉综合征临床研究
|
摘要
目的探讨普罗布考联合阿托伐他汀对急性冠脉综合征患者血脂代谢及血清N端前脑利钠肽(NT-proBNP)、超敏C反应蛋白(hs-CRP)、血小板功能的影响。方法选取医院2016年1月至2017年1月收治的急性冠脉综合征患者90例,按照随机数字表法分为对照组和观察组,各45例。两组均给予常规治疗,对照组患者给予阿托伐他汀,观察组患者在对照组基础上给予普罗布考。结果治疗后,两组患者三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、NT-proBNP、hs-CRP水平均明显低于治疗前(P <0.05),高密度脂蛋白胆固醇(HDL-C)水平明显高于治疗前(P <0.05),且观察组上述指标明显优于对照组(P <0.05);两组患者治疗前后血浆可溶性P选择素(sP-S)水平比较均无统计学差异(P> 0.05);随访6个月观察组患者发生血管疾病风险事件发生率为11.11%,明显低于对照组的31.11%(χ~2=5.404,P=0.020)。结论普罗布考联合阿托伐他汀可有效降低急性冠脉综合征患者的血脂和体内炎性水平,改善预后。
Objective To investigate the effect of probucol combined with atorvastatin on serum lipid metabolism, serum N-terminal pro-brain natriuretic peptide(NT-proBNP),high-sensitivity C-reactive protein(hs-CRP) and platelet function in patients with acute coronary syndrome.Methods Totally 90 patients with acute coronary syndrome admitted to our hospital from January 2016 to January2017 were selected and divided into the control group and the observation group according to the random number table method,45 cases in each group.The patients in the two groups were given routine treatment,the patients in the control group were given atorvastatin,on this basis, the patients in the observation group were given probucol.Results After treatment, the levels of triglyceride(TG), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C), NT-proBNP and hs-CRP in the two groups were significantly lower than those before treatment(P < 0.05), while the levels of high-density lipoprotein cholesterol(HDL-C) in the two groups were significantly higher than those before treatment(P < 0.05), and the above indexes in the observation group were significantly better than those in the control group(P < 0.05).There was no significant difference in plasma soluble P selectin(sP-S) levels between the two groups before and after treatment(P > 0.05).After 6 months of follow-up,the incidence rate of vascular disease risk events in the observation group was 11.11 %, which was sig nificantly lower than 31.11 % in the control group(χ~2= 5.404, P = 0.020).Conclusion Probucol combined with atorvastatin can effectively reduce blood lipid level and inflammatory level,and improve prognosis in patients with acute coronary syndrome.
Objective To investigate the effect of probucol combined with atorvastatin on serum lipid metabolism, serum N-terminal pro-brain natriuretic peptide(NT-proBNP),high-sensitivity C-reactive protein(hs-CRP) and platelet function in patients with acute coronary syndrome.Methods Totally 90 patients with acute coronary syndrome admitted to our hospital from January 2016 to January2017 were selected and divided into the control group and the observation group according to the random number table method,45 cases in each group.The patients in the two groups were given routine treatment,the patients in the control group were given atorvastatin,on this basis, the patients in the observation group were given probucol.Results After treatment, the levels of triglyceride(TG), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C), NT-proBNP and hs-CRP in the two groups were significantly lower than those before treatment(P < 0.05), while the levels of high-density lipoprotein cholesterol(HDL-C) in the two groups were significantly higher than those before treatment(P < 0.05), and the above indexes in the observation group were significantly better than those in the control group(P < 0.05).There was no significant difference in plasma soluble P selectin(sP-S) levels between the two groups before and after treatment(P > 0.05).After 6 months of follow-up,the incidence rate of vascular disease risk events in the observation group was 11.11 %, which was sig nificantly lower than 31.11 % in the control group(χ~2= 5.404, P = 0.020).Conclusion Probucol combined with atorvastatin can effectively reduce blood lipid level and inflammatory level,and improve prognosis in patients with acute coronary syndrome.
引文
[1]JIA S,ZHOU YJ,YU Y,et al.Obstructive sleep apnea is associated with severity and long-term prognosis of acute coronary syndrome[J].Geriatr Cardiol,2018,15(2):146-152.
[2]GORYO Y,KUME T,UEDA T,et al.Vascular Healing Response after Everolimus-Eluting Stent Implantation in Acute Coronary Syndrome Culprit Lesions:Comparison with Implantation in Stable Angina Pectoris[J].Acta Cardiol Sin,2018,34(2):124-129.
[3]KOURBELIS C,FRANZON J,FOOTE J,et al.Effectiveness of discharge education on outcomes in acute coronary syndrome patients:a systematic review protocol[J].JBI Database System Rev Implement Rep,2018,16(4):817-824.
[4]张建平,林卫,王云峰.阿托伐他汀对2型糖尿病血脂、血糖的调节作用及抗动脉粥样硬化、炎性反应效果评价[J].中国药业,2017,26(8):49-51.
[5]吕艳芳.瑞舒伐他汀联合普罗布考治疗老年期脑梗死对患者颈动脉粥样硬化与血脂及血浆炎性因子的影响[J].中国实用神经疾病杂志,2017,20(4):110-112.
[6]YOUSSEF GS,KASSEM HH,AMEEN OA,et al.Pre-hospital and hospital delay in patients with non-ST elevation acute coronary syndromes in tertiary care[J].Egypt Heart J,2017,69(3):177-181.
[7]马冰宁.急性冠脉综合征患者GRACE评分与心血管危险因素的相关性[J].广东医学,2015,36(16):2507-2510.
[8]魏霞,陈还珍,刘子源,等.急性冠脉综合征患者危险因素与冠状动脉病变的相关性研究[J].中西医结合心脑血管病杂志,2015,13(6):798-802.
[9]梁娟.急性冠脉综合征PCI术后早期恶性室性心律失常的危险因素分析[J].陕西医学杂志,2017,46(10):1415-1416.
[10]王威,吴华雄.急性冠脉综合征的危险因素分析[J].中国当代医药,2015,22(5):39-41.
[11]刘瑞.瑞舒伐他汀和阿托伐他汀对冠心病患者的临床疗效及对血清中IL-35、NF-κB水平影响的比较[J].药物评价研究,2017,40(8):1141-1144.
[12]马艳丽.瑞舒伐他汀和阿托伐他汀治疗不稳定心绞痛的疗效对比研究[J].中国冶金工业医学杂志,2018,35(1):122-123.
[13]王月华,赵芳霞.阿托伐他汀对2型糖尿病伴心肌病患者左室功能和心脏不良事件的影响[J].中国药业,2018,27(8):43-45.
[14]付茜.阿托伐他汀钙治疗老年脑动脉硬化49例临床研究[J].中国药业,2016,25(9):59-61.
[15]张丽,田苗,刘福兴.普罗布考对脑梗死进展期患者APTT、FIB与血液流变学的影响[J].川北医学院学报,2017,32(1):102-105.
[16]李锦,林璋.普罗布考联合阿托伐他汀治疗高龄老年患者颈动脉硬化斑块的疗效观察[J].海峡药学,2017,29(2):101-102.
[17]陈海萍,黄辉,蒋金法.普罗布考对急性冠状动脉综合征患者的抗炎抗氧化作用[J].上海医学,2014,37(7):574-576.
[2]GORYO Y,KUME T,UEDA T,et al.Vascular Healing Response after Everolimus-Eluting Stent Implantation in Acute Coronary Syndrome Culprit Lesions:Comparison with Implantation in Stable Angina Pectoris[J].Acta Cardiol Sin,2018,34(2):124-129.
[3]KOURBELIS C,FRANZON J,FOOTE J,et al.Effectiveness of discharge education on outcomes in acute coronary syndrome patients:a systematic review protocol[J].JBI Database System Rev Implement Rep,2018,16(4):817-824.
[4]张建平,林卫,王云峰.阿托伐他汀对2型糖尿病血脂、血糖的调节作用及抗动脉粥样硬化、炎性反应效果评价[J].中国药业,2017,26(8):49-51.
[5]吕艳芳.瑞舒伐他汀联合普罗布考治疗老年期脑梗死对患者颈动脉粥样硬化与血脂及血浆炎性因子的影响[J].中国实用神经疾病杂志,2017,20(4):110-112.
[6]YOUSSEF GS,KASSEM HH,AMEEN OA,et al.Pre-hospital and hospital delay in patients with non-ST elevation acute coronary syndromes in tertiary care[J].Egypt Heart J,2017,69(3):177-181.
[7]马冰宁.急性冠脉综合征患者GRACE评分与心血管危险因素的相关性[J].广东医学,2015,36(16):2507-2510.
[8]魏霞,陈还珍,刘子源,等.急性冠脉综合征患者危险因素与冠状动脉病变的相关性研究[J].中西医结合心脑血管病杂志,2015,13(6):798-802.
[9]梁娟.急性冠脉综合征PCI术后早期恶性室性心律失常的危险因素分析[J].陕西医学杂志,2017,46(10):1415-1416.
[10]王威,吴华雄.急性冠脉综合征的危险因素分析[J].中国当代医药,2015,22(5):39-41.
[11]刘瑞.瑞舒伐他汀和阿托伐他汀对冠心病患者的临床疗效及对血清中IL-35、NF-κB水平影响的比较[J].药物评价研究,2017,40(8):1141-1144.
[12]马艳丽.瑞舒伐他汀和阿托伐他汀治疗不稳定心绞痛的疗效对比研究[J].中国冶金工业医学杂志,2018,35(1):122-123.
[13]王月华,赵芳霞.阿托伐他汀对2型糖尿病伴心肌病患者左室功能和心脏不良事件的影响[J].中国药业,2018,27(8):43-45.
[14]付茜.阿托伐他汀钙治疗老年脑动脉硬化49例临床研究[J].中国药业,2016,25(9):59-61.
[15]张丽,田苗,刘福兴.普罗布考对脑梗死进展期患者APTT、FIB与血液流变学的影响[J].川北医学院学报,2017,32(1):102-105.
[16]李锦,林璋.普罗布考联合阿托伐他汀治疗高龄老年患者颈动脉硬化斑块的疗效观察[J].海峡药学,2017,29(2):101-102.
[17]陈海萍,黄辉,蒋金法.普罗布考对急性冠状动脉综合征患者的抗炎抗氧化作用[J].上海医学,2014,37(7):574-576.